Rovina Ruslami

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults

Dick Menzies, Mênonli Adjobimey, Rovina Ruslami et al. · New England Journal of Medicine · 2018 · 386 citations · Full text

Public Health, Pharmacotherapy, Antimicrobial Pharmacotherapy +16

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

Rovina Ruslami, Ahmad Rizal Ganiem, Sofiati Dian et al. · The Lancet Infectious Diseases · 2012 · 352 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

Hanneke M. J. Nijland, Rovina Ruslami, Janneke E. Stalenhoef et al. · Clinical Infectious Diseases · 2006 · 241 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8

Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients

Rovina Ruslami, Hanneke M. J. Nijland, Bachti Alisjahbana et al. · Antimicrobial Agents and Chemotherapy · 2007 · 179 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Hanneke M. J. Nijland, Rovina Ruslami, A. J. Suroto et al. · Clinical Infectious Diseases · 2007 · 170 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16